• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

模拟免疫复合物以实现高效抗体反应。

Mimicking immune complexes for efficient antibody responses.

作者信息

Schönfelder Jonathan, El Ayoubi Omar, Havryliuk Oles, Groß Rüdiger, Seidel Alina, Bakchoul Tamam, Münch Jan, Jumaa Hassan, Setz Corinna S

机构信息

Institute of Immunology, Ulm University Medical Center, Ulm, Germany.

Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.

出版信息

Front Immunol. 2025 Apr 28;16:1570487. doi: 10.3389/fimmu.2025.1570487. eCollection 2025.

DOI:10.3389/fimmu.2025.1570487
PMID:40356891
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12066251/
Abstract

Efficient antibody responses are crucial for combating infectious diseases and vaccination remains a cornerstone of this effort. This study introduces a novel approach for enhancing immune responses in wild-type mice by utilizing pre-formed immune complexes, using the receptor-binding domain (RBD) of SARS-CoV-2 as a model antigen to illustrate the broader potential of the concept. Specifically, we found that pre-treating the antigen with bis-maleimide, a chemical linker that facilitates protein cross-linking, significantly enhances antibody production. Moreover, cross-linking of antigen to unrelated IgG using bis-maleimide generated immune complexes that markedly enhanced antigen-specific antibody responses, likely by mimicking natural memory-like mechanisms, suggesting that bis-maleimide pre-treated antigens may similarly engage IgG . In contrast, antigen crosslinking with IgA or IgM did not yield comparable effects, highlighting the unique capacity of IgG to boost immunogenicity. By leveraging the principles of immune memory, this study demonstrates the potential of pre-formed immune complexes to significantly enhance vaccine efficacy using an antigen-independent strategy broadly applicable to diverse pathogens.

摘要

高效的抗体反应对于对抗传染病至关重要,而疫苗接种仍然是这项工作的基石。本研究引入了一种新方法,通过利用预先形成的免疫复合物来增强野生型小鼠的免疫反应,以严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的受体结合域(RBD)作为模型抗原来说明这一概念的更广泛潜力。具体而言,我们发现用双马来酰亚胺(一种促进蛋白质交联的化学连接剂)预处理抗原可显著提高抗体产生。此外,使用双马来酰亚胺将抗原与无关的免疫球蛋白G(IgG)交联产生的免疫复合物显著增强了抗原特异性抗体反应,可能是通过模拟天然记忆样机制,这表明双马来酰亚胺预处理的抗原可能同样与IgG相互作用。相比之下,抗原与免疫球蛋白A(IgA)或免疫球蛋白M(IgM)交联未产生类似效果,突出了IgG增强免疫原性的独特能力。通过利用免疫记忆原理,本研究证明了预先形成的免疫复合物使用广泛适用于多种病原体的抗原非依赖性策略显著提高疫苗效力的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43e4/12066251/156264189c8e/fimmu-16-1570487-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43e4/12066251/2b1292bac4a9/fimmu-16-1570487-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43e4/12066251/5254a6244161/fimmu-16-1570487-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43e4/12066251/6bee01707605/fimmu-16-1570487-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43e4/12066251/7c79f4f6223a/fimmu-16-1570487-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43e4/12066251/bf67e8866d89/fimmu-16-1570487-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43e4/12066251/156264189c8e/fimmu-16-1570487-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43e4/12066251/2b1292bac4a9/fimmu-16-1570487-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43e4/12066251/5254a6244161/fimmu-16-1570487-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43e4/12066251/6bee01707605/fimmu-16-1570487-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43e4/12066251/7c79f4f6223a/fimmu-16-1570487-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43e4/12066251/bf67e8866d89/fimmu-16-1570487-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43e4/12066251/156264189c8e/fimmu-16-1570487-g006.jpg

相似文献

1
Mimicking immune complexes for efficient antibody responses.模拟免疫复合物以实现高效抗体反应。
Front Immunol. 2025 Apr 28;16:1570487. doi: 10.3389/fimmu.2025.1570487. eCollection 2025.
2
Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.根据 BNT162b2 疫苗接种和感染史,抗 SARS-CoV-2 免疫球蛋白同种型和对病毒变异体的中和活性。
Front Immunol. 2021 Dec 17;12:793191. doi: 10.3389/fimmu.2021.793191. eCollection 2021.
3
Evolution of antibody immunity to SARS-CoV-2.SARS-CoV-2 抗体免疫的演变。
Nature. 2021 Mar;591(7851):639-644. doi: 10.1038/s41586-021-03207-w. Epub 2021 Jan 18.
4
Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.利用多冠状病毒蛋白微阵列在 COVID-19 患者中绘制 SARS-CoV-2 抗体表位图谱。
Microbiol Spectr. 2021 Oct 31;9(2):e0141621. doi: 10.1128/Spectrum.01416-21. Epub 2021 Oct 27.
5
Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination.BNT162b2 或 mRNA-1273 异源加强接种后 SARS-CoV-2 IgA、IgG、中和和总抗体反应的随访和比较评估。
Influenza Other Respir Viruses. 2024 May;18(5):e13290. doi: 10.1111/irv.13290.
6
Development of a high-sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARS-CoV-2 spike glycoprotein in serum and saliva.开发一种高灵敏度 ELISA 检测血清和唾液中针对 SARS-CoV-2 刺突糖蛋白的 IgG、IgA 和 IgM 抗体。
Immunology. 2021 Sep;164(1):135-147. doi: 10.1111/imm.13349. Epub 2021 May 24.
7
Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles.在乌干达人中观察到针对 ChAdOx1-S 牛津-阿斯利康(ChAdOx1-S,Covishield)SARS-CoV-2 疫苗的持久和强大的抗体反应,这些人具有不同的基线免疫特征。
PLoS One. 2024 Jul 29;19(7):e0303113. doi: 10.1371/journal.pone.0303113. eCollection 2024.
8
Differential Antibody Response to SARS-CoV-2 Antigens in Recovered and Deceased Iranian COVID-19 Patients.伊朗 COVID-19 康复和死亡患者对 SARS-CoV-2 抗原的抗体反应差异。
Viral Immunol. 2021 Dec;34(10):708-713. doi: 10.1089/vim.2021.0061. Epub 2021 Sep 17.
9
S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit.人类感染 SARS-CoV-2 后 S 蛋白反应性 IgG 和记忆 B 细胞的产生包括对 S2 亚基的广泛反应性。
mBio. 2020 Sep 25;11(5):e01991-20. doi: 10.1128/mBio.01991-20.
10
Systems serology detects functionally distinct coronavirus antibody features in children and elderly.系统血清学在儿童和老年人中检测到功能不同的冠状病毒抗体特征。
Nat Commun. 2021 Apr 1;12(1):2037. doi: 10.1038/s41467-021-22236-7.

本文引用的文献

1
Conversion of vaccines from low to high immunogenicity by antibodies with epitope complementarity.通过具有表位互补性的抗体将疫苗从低免疫原性转化为高免疫原性。
Immunity. 2024 Oct 8;57(10):2433-2452.e7. doi: 10.1016/j.immuni.2024.08.017. Epub 2024 Sep 20.
2
How B cells drive T-cell responses: A key role for cross-presentation of antibody-targeted antigens.B 细胞如何驱动 T 细胞反应:抗体靶向抗原的交叉呈递起着关键作用。
Adv Immunol. 2023;160:37-57. doi: 10.1016/bs.ai.2023.09.002. Epub 2023 Nov 18.
3
Profound structural conservation of chemically cross-linked HIV-1 envelope glycoprotein experimental vaccine antigens.
化学交联的HIV-1包膜糖蛋白实验性疫苗抗原的深度结构保守性
NPJ Vaccines. 2023 Jul 13;8(1):101. doi: 10.1038/s41541-023-00696-w.
4
Antigen footprint governs activation of the B cell receptor.抗原足迹决定 B 细胞受体的激活。
Nat Commun. 2023 Feb 22;14(1):976. doi: 10.1038/s41467-023-36672-0.
5
Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial.抗逆转录病毒治疗起始时使用 3BNC117 和罗米地辛对 HIV-1 感染者进行早期干预:一项 1b/2a 期、随机试验。
Nat Med. 2022 Nov;28(11):2424-2435. doi: 10.1038/s41591-022-02023-7. Epub 2022 Oct 17.
6
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.抗 SARS-CoV-2 疫苗 SOBERANA 02 同源或异源方案的安全性和免疫原性:开放标签 I 期和 IIa 期临床试验。
Vaccine. 2022 Jul 29;40(31):4220-4230. doi: 10.1016/j.vaccine.2022.05.082. Epub 2022 Jun 6.
7
Mechanisms of SARS-CoV-2 entry into cells.SARS-CoV-2 进入细胞的机制。
Nat Rev Mol Cell Biol. 2022 Jan;23(1):3-20. doi: 10.1038/s41580-021-00418-x. Epub 2021 Oct 5.
8
SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies.SARS-CoV-2 RBD-破伤风类毒素缀合物疫苗在临床前研究中诱导出强烈的中和免疫反应。
ACS Chem Biol. 2021 Jul 16;16(7):1223-1233. doi: 10.1021/acschembio.1c00272. Epub 2021 Jul 4.
9
Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic.SARS-CoV-2 引发 COVID-19 大流行一年后的经验教训。
Emerg Microbes Infect. 2021 Dec;10(1):507-535. doi: 10.1080/22221751.2021.1898291.
10
Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C).绘制儿童多系统炎症综合征(MIS-C)中的系统性炎症和抗体反应图谱。
Cell. 2020 Nov 12;183(4):982-995.e14. doi: 10.1016/j.cell.2020.09.034. Epub 2020 Sep 14.